Suppr超能文献

双相情感障碍患者肥胖管理的干预措施。

Interventions for the management of obesity in people with bipolar disorder.

作者信息

Tully Agnes, Smyth Siobhan, Conway Yvonne, Geddes John, Devane Declan, Kelly John P, Jordan Fionnuala

机构信息

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.

Department of Psychiatry, University of Oxford, Oxford, UK.

出版信息

Cochrane Database Syst Rev. 2020 Jul 20;7(7):CD013006. doi: 10.1002/14651858.CD013006.pub2.

Abstract

BACKGROUND

Bipolar disorder is one of the most common serious mental illnesses, affecting approximately 60 million people worldwide. Characterised by extreme alterations in mood, cognition, and behaviour, bipolar disorder can have a significant negative impact on the functioning and quality of life of the affected individual. Compared with the general population, the prevalence of comorbid obesity is significantly higher in bipolar disorder. Approximately 68% of treatment seeking bipolar patients are overweight or obese. Clinicians are aware that obesity has the potential to contribute to other physical health conditions in people with bipolar disorder, including diabetes, hypertension, metabolic syndrome, cardiovascular disease, and coronary heart disease. Cardiovascular disease is the leading cause of premature death in bipolar disorder, happening a decade or more earlier than in the general population. Contributing factors include illness-related factors (mood-related factors, i.e. mania or depression), treatment-related factors (weight implications and other side effects of medications), and lifestyle factors (physical inactivity, poor diet, smoking, substance abuse). Approaches to the management of obesity in individuals with bipolar disorder are diverse and include non-pharmacological interventions (i.e. dietary, exercise, behavioural, or multi-component), pharmacological interventions (i.e. weight loss drugs or medication switching), and bariatric surgery.

OBJECTIVES

To assess the effectiveness of interventions for the management of obesity in people with bipolar disorder.

SEARCH METHODS

We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) and the Cochrane Central Register for Controlled Trials (CENTRAL) to February 2019. We ran additional searches via Ovid databases including MEDLINE, Embase, and PsycInfo to May 2020. We searched the World Health Organization (WHO) trials portal (International Clinical Trials Registry Platform (ICTRP)) and ClinicalTrials.gov. We also checked the reference lists of all papers brought to full-text stage and all relevant systematic reviews.

SELECTION CRITERIA

Randomised controlled trials (RCTs), randomised at the level of the individual or cluster, and cross-over designs of interventions for management of obesity, in which at least 80% of study participants had a clinical diagnosis of bipolar disorder and comorbid obesity (body mass index (BMI) ≥ 30 kg/m²), were eligible for inclusion. No exclusions were based on type of bipolar disorder, stage of illness, age, or gender. We included non-pharmacological interventions comprising dietary, exercise, behavioural, and multi-component interventions; pharmacological interventions consisting of weight loss medications and medication switching interventions; and surgical interventions such as gastric bypass, gastric bands, biliopancreatic diversion, and vertical banded gastroplasty. Comparators included the following approaches: dietary intervention versus inactive comparator; exercise intervention versus inactive comparator; behavioural intervention versus inactive comparator; multi-component lifestyle intervention versus inactive comparator; medication switching intervention versus inactive comparator; weight loss medication intervention versus inactive comparator; and surgical intervention versus inactive comparator. Primary outcomes of interest were changes in body mass, patient-reported adverse events, and quality of life.

DATA COLLECTION AND ANALYSIS

Four review authors were involved in the process of selecting studies. Two review authors independently screened the titles and abstracts of studies identified in the search. Studies brought to the full-text stage were then screened by another two review authors working independently. However, none of the full-text studies met the inclusion criteria. Had we included studies, we would have assessed their methodological quality by using the criteria recommended in the Cochrane Handbook for Systematic Reviews of Interventions. We intended to combine dichotomous data using risk ratios (RRs), and continuous data using mean differences (MDs). For each outcome, we intended to calculate overall effect size with 95% confidence intervals (CIs).

MAIN RESULTS

None of the studies that were screened met the inclusion criteria.

AUTHORS' CONCLUSIONS: None of the studies that were assessed met the inclusion criteria of this review. Therefore we were unable to determine the effectiveness of interventions for the management of obesity in individuals with bipolar disorder. Given the extent and impact of the problem and the absence of evidence, this review highlights the need for research in this area. We suggest the need for RCTs that will focus only on populations with bipolar disorder and comorbid obesity. We identified several ongoing studies that may be included in the update of this review.

摘要

背景

双相情感障碍是最常见的严重精神疾病之一,全球约有6000万人受其影响。双相情感障碍的特征是情绪、认知和行为的极端变化,会对受影响个体的功能和生活质量产生重大负面影响。与普通人群相比,双相情感障碍患者中合并肥胖的患病率显著更高。约68%寻求治疗的双相情感障碍患者超重或肥胖。临床医生意识到肥胖有可能导致双相情感障碍患者出现其他身体健康问题,包括糖尿病、高血压、代谢综合征、心血管疾病和冠心病。心血管疾病是双相情感障碍患者过早死亡的主要原因,比普通人群早十年或更早出现。促成因素包括疾病相关因素(与情绪相关的因素,即躁狂或抑郁)、治疗相关因素(药物的体重影响和其他副作用)以及生活方式因素(缺乏运动、饮食不良、吸烟、药物滥用)。双相情感障碍患者肥胖的管理方法多种多样,包括非药物干预(即饮食、运动、行为或多成分干预)、药物干预(即减肥药物或换药)和减肥手术。

目的

评估双相情感障碍患者肥胖管理干预措施的有效性。

检索方法

我们检索了截至2019年2月的Cochrane常见精神障碍对照试验注册库(CCMDCTR)和Cochrane对照试验中央注册库(CENTRAL)。我们通过Ovid数据库(包括MEDLINE、Embase和PsycInfo)进行了额外检索,截至2020年5月。我们检索了世界卫生组织(WHO)试验平台(国际临床试验注册平台(ICTRP))和ClinicalTrials.gov。我们还检查了所有进入全文阶段的论文以及所有相关系统评价的参考文献列表。

选择标准

个体或整群随机的随机对照试验(RCT)以及肥胖管理干预措施的交叉设计,其中至少80%的研究参与者临床诊断为双相情感障碍并合并肥胖(体重指数(BMI)≥30kg/m²),符合纳入标准。不基于双相情感障碍类型、疾病阶段、年龄或性别进行排除。我们纳入了非药物干预措施,包括饮食、运动、行为和多成分干预;药物干预措施,包括减肥药物和换药干预;以及手术干预措施,如胃旁路手术、胃束带术、胆胰分流术和垂直束带胃成形术。对照包括以下方法:饮食干预与无活性对照;运动干预与无活性对照;行为干预与无活性对照;多成分生活方式干预与无活性对照;换药干预与无活性对照;减肥药物干预与无活性对照;以及手术干预与无活性对照。感兴趣的主要结局是体重变化、患者报告的不良事件和生活质量。

数据收集与分析

四位综述作者参与了研究选择过程。两位综述作者独立筛选检索中识别出的研究的标题和摘要。然后由另外两位独立工作的综述作者对进入全文阶段的研究进行筛选。然而,没有一篇全文研究符合纳入标准。如果我们纳入了研究,我们会使用Cochrane干预措施系统评价手册中推荐的标准评估其方法学质量。我们打算使用风险比(RRs)合并二分数据,使用均值差(MDs)合并连续数据。对于每个结局指标,我们打算计算总体效应量及95%置信区间(CIs)。

主要结果

筛选的研究均未符合纳入标准。

作者结论

评估的研究均未符合本综述的纳入标准。因此,我们无法确定双相情感障碍患者肥胖管理干预措施的有效性。鉴于该问题的范围和影响以及缺乏证据,本综述强调了该领域研究的必要性。我们建议开展仅针对双相情感障碍合并肥胖人群的随机对照试验。我们确定了几项正在进行的研究,可能会纳入本综述的更新版本。

相似文献

1
Interventions for the management of obesity in people with bipolar disorder.
Cochrane Database Syst Rev. 2020 Jul 20;7(7):CD013006. doi: 10.1002/14651858.CD013006.pub2.
4
Bariatric surgery: an evidence-based analysis.
Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 1.
6
7
Behavioural interventions for type 2 diabetes: an evidence-based analysis.
Ont Health Technol Assess Ser. 2009;9(21):1-45. Epub 2009 Oct 1.
8
E-Health interventions for anxiety and depression in children and adolescents with long-term physical conditions.
Cochrane Database Syst Rev. 2018 Aug 15;8(8):CD012489. doi: 10.1002/14651858.CD012489.pub2.
9
Drug interventions for the treatment of obesity in children and adolescents.
Cochrane Database Syst Rev. 2016 Nov 29;11(11):CD012436. doi: 10.1002/14651858.CD012436.

引用本文的文献

2
Pilot study of a ketogenic diet in bipolar disorder: a process evaluation.
BMC Psychiatry. 2025 Jan 21;25(1):63. doi: 10.1186/s12888-025-06479-y.
6
Communication about weight-related issues with adult patients with obesity in general practice: A scoping review.
Obes Sci Pract. 2023 Apr 10;9(5):548-570. doi: 10.1002/osp4.669. eCollection 2023 Oct.
7
Self-management interventions for adults living with obesity to improve patient-relevant outcomes: An evidence map.
Patient Educ Couns. 2023 May;110:107647. doi: 10.1016/j.pec.2023.107647. Epub 2023 Jan 24.
9
Neighborhood deprivation and coronary heart disease in patients with bipolar disorder.
Sci Rep. 2022 Oct 6;12(1):16763. doi: 10.1038/s41598-022-21295-0.
10
Prevalence and associated factors of obesity and overweight in Chinese patients with bipolar disorder.
Front Psychiatry. 2022 Sep 6;13:984829. doi: 10.3389/fpsyt.2022.984829. eCollection 2022.

本文引用的文献

1
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness.
Lancet Psychiatry. 2019 Aug;6(8):675-712. doi: 10.1016/S2215-0366(19)30132-4. Epub 2019 Jul 16.
2
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014.
Br J Psychiatry. 2017 Sep;211(3):175-181. doi: 10.1192/bjp.bp.117.202606. Epub 2017 Jul 6.
8
Pharmacotherapy for the management of obesity.
Metabolism. 2015 Nov;64(11):1376-85. doi: 10.1016/j.metabol.2015.08.001. Epub 2015 Aug 12.
10
Past and present of antiobesity agents: focus on monoamine modulators.
Am J Health Syst Pharm. 2015 May 1;72(9):697-706. doi: 10.2146/ajhp140034.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验